UPDATE 1-Sanofi settles further Eloxatin patent suits

* Settlement relates to Mayne/Hospira, MN/Par and Actavis

* Deal also reached with Sun Pharmaceuticals

(Adds detail)

PARIS, April 6 (BestGrowthStock) – Sanofi-Aventis (SASY.PA: ) has
settled a patent law suit over cancer drug Eloxatin with
additional drugmakers, stopping them selling their generic
versions in the United States from June 30 until August 2012.

The agreement announced on Tuesday relates to Mayne/Hospira
(HSP.N: ), MN/Par and Actavis and follows similar settlements with
Teva Pharmaceuticals (TEVA.TA: ), Fresenius Kabi (APCVZ.O: ) and
Novartis’ (NOVN.VX: ) Sandoz unit unveiled last week.
[ID:nLDE63002M]

The suits came after generic drugmakers launched a cheaper
copy earlier than expected last year that eroded sales of
Eloxatin.

Sanofi-Aventis said in a statement the generic companies
would in 2012 launch an officially licensed version of
injectable Eloxatin, whose generic name is oxaliplatin.

The rest of the settlement provisions are confidential,
Sanofi said. The deal requires approval from the U.S. Federal
Trade Commission and the U.S. Department of Justice.

Sanofi added that Sun Pharmaceuticals (SUN.BO: ) had also
agreed to stop selling their Eloxatin generic during the same
period.

Eloxatin sales in the fourth quarter of last year
represented 1.1 percent of Sanofi’s total pharma sales, with
U.S. sales of the product down 97 percent at 7 million euros
($9.43 million).

For the full year, Eloxatin sales fell more than a third at
constant exchange rates to 957 million euros.

Investing

($1=.7422 Euro)
(Reporting by James Regan; Editing by Jon Loades-Carter)

UPDATE 1-Sanofi settles further Eloxatin patent suits